Preprint Hypothesis Version 1 This version is not peer-reviewed

Ace Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?

Version 1 : Received: 8 April 2020 / Approved: 9 April 2020 / Online: 9 April 2020 (12:34:46 CEST)
Version 2 : Received: 21 April 2020 / Approved: 22 April 2020 / Online: 22 April 2020 (09:46:54 CEST)

How to cite: Focosi, D.; Tuccori, M.; Maggi, F. Ace Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints 2020, 2020040151 (doi: 10.20944/preprints202004.0151.v1). Focosi, D.; Tuccori, M.; Maggi, F. Ace Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?. Preprints 2020, 2020040151 (doi: 10.20944/preprints202004.0151.v1).

Abstract

Human respiratory beta coronavirus are emerging causes for Public Health Emergencies of International Concern (PHEIC). SARS-CoV2 is circulating worldwide since November 2019. We review here the cardiovascular morbidity and mortality in COVID-19, and data supporting the role for dysregulation of the RAS counterregulatory axis due to binding of SARS-CoV2 S protein to ACE2 receptor. Since this counterregulatory axis provides benefits not only on the cardiovascular front but also in acute lung injury, we speculate on potential use of ACE inhibitors and AT1R blockers in critically ill COVID-19 patients, and report current evidences.

Subject Areas

COVID-19; ACEI; ARB; SARS; ALI; ARDS

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.